Glucosamine + Chondroitin + Fatty Acids + Vitamins

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
2
Deaths Reported
1250.0%
Death Rate

Active Ingredients

Glucosamine + Chondroitin + Fatty Acids + Vitamins

Administration Routes

OralUnknown

Species Affected

Dog 16

Most Affected Breeds

Boxer (German Boxer) 2
Retriever - Labrador 2
Bulldog 1
Chihuahua 1
Dachshund - Standard Long-haired 1
Dachshund - Standard Smooth-haired 1
Siberian Husky 1
Corgi (unspecified) 1
Maltese 1
Bichon Frise 1

Most Reported Reactions

Emesis 7
Decreased appetite 2
Diarrhoea 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Hyperphosphataemia 2
Vomiting 2
Itching 1
Pruritus 1
Diabetes 1
Weight loss 1
INEFFECTIVE, HEARTWORM LARVAE 1
Panting 1

Outcome Breakdown

Recovered/Normal
11 (68.8%)
Recovered with Sequela
2 (12.5%)
Ongoing
1 (6.3%)
Euthanized
1 (6.3%)
Died
1 (6.3%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 2
Case-fatality rate (reported events) 1250.0%
Distinct species in reports 1
Distinct breeds in reports 14
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Glucosamine + Chondroitin + Fatty Acids + Vitamins Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing Glucosamine + Chondroitin + Fatty Acids + Vitamins, including 2 reports in which the animal died — a 1250.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Glucosamine + Chondroitin + Fatty Acids + Vitamins. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Glucosamine + Chondroitin + Fatty Acids + Vitamins reports are Dog (16 reports), with Dog accounting for the largest share. Within those species, Boxer (German Boxer) (2), Retriever - Labrador (2), Bulldog (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Glucosamine + Chondroitin + Fatty Acids + Vitamins are Emesis (7), Decreased appetite (2), Diarrhoea (2), Lethargy (see also Central nervous system depression in 'Neurological') (2). Of the 16 reports with a coded outcome, Recovered/Normal is the leading category at 68.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Glucosamine + Chondroitin + Fatty Acids + Vitamins.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial